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time of recruitment (T0), after each intrarticular infiltration (T1, T2,
T3) and 3 month later of the last infiltration (T4).
Results Both groups showed a progressive improvement of pain
(VAS scale) and reduction of Womac scale. During follow-up,
3 months after the last infiltration, the data results statistically better
in group A vs. group B.
Conclusions The ecoguided infiltrations with high molecular weight
integrated with oral chondroprotective supplements in mild-moderate
primary osteoarthritis show a synergistic effect, allowing the reduc-
tion of the pain and the functionality of the hip. 1. Mechanical injury
suppresses autophagy regulators and its pharmacological activation
results in chondroprotection.
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Introduction The risk of thromboembolic events for patients who
have undergone a total hip arthroplasty is about of 45–70 % without a
prophylaxis, for this reason a specific thromboprophylaxis is recom-
mended. The use of low-molecular-weight heparins is often
characterized by a poor compliance with reference to a subcutaneous
administration. The dabigatran etexilate is a direct thrombin inhibitor
administered by mouth. The objective of this research is to test a
selected population of patients subjected to a primary prophylaxis by
Dabigatran Etexilate after total hip arthroplasty.
Materials and methods Since November 2010 to December 2011 we
carried out a primary thromboembolic prophylaxis by Dabigatran
Etexilate with 80 patients who underwent a first total hip arthroplasty.
We underwent a retrospective analysis evaluating all the medical
records, the outpatient controls after 1–3 months from the operation
and a final phone interview. We left off the patients with a moderate
or heavy kidney insufficiency, liver insufficiency, coagulation alter-
ations, uncontrolled hypertension, acute ischemic stroke in the
previous 6 months, cases of hemorrhagic stroke in the previous
6 months, gastrointestinal or urogenital bleedings. We also excluded
patients subjected to a therapy with oral anticoagulants, antiaggre-
gants (except ASA). The dosage was of 220 mg daily for patients
under 75 and 150 mg daily for patients over 75, prophylaxis was
continuated for 35 days. Collected data: length of the operation, blood
loss, haemocrome pre-op. and V gg post-op., surgical drain, blood
transfusion, length of the immobilization, post-surgical haematomas,
symptomatic Deep Vein Thrombosis appearance, PE major-minor
bleedings, adverse events, satisfaction, compliance.
Results No events of PE, of mortality correlated to thromboembolic
events, one case of Deep Vein Thrombosis, two cases of major
bleeding, no major adverse reactions. All the patients, except the
patients with DVT, completed the therapy.
Discussion The Dabigatran Etexilate has shown its efficacy and
safety, not lower than what we learn in literature, for the LMWHs.
The compliance and satisfaction for the oral therapy have been higher
than what is reported in literature as to a subcutaneous consumption
of LMWHs.
Conclusions By a retrospective analysis of the selected patients the
Dabigatran Etexilate will be an effective alternative to the use of
LMWHs for both its efficacy and safety. The examined patients have
shown a higher compliance and pleasure for the oral therapy as to a
hypothetical subcutaneous one.
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Introduction The early dislocation of THA is one of the most feared
complications with an incidence reported in literature from 2 to 5 %.
This event is related to several risk factors related both to the patient
and to the surgery and to prosthetic design. The aim of our study is to
analyze these risk factors and their influence in dislocation.
Materials and methods We analized a total of 387 primary THA in
375 patients performed between September 2005 to Dicember 2008 at
our institute with femoral head size of 28 and 32 mm and two types of
cups, TMT and Trilogy, all were implanted by the posterolateral
approach. All patients except 53 had coxarthrosis as preoperative
diagnosis. We analyzed sex, age, biometric index and BMI as factors
related to the patient. For clinical evaluation we used the Harris Hip
Score. The measurement of the femoral offset, abduction and ante-
version angle of the cup were realized by radiographyic evaluation.
Results We have had 6 dislocations (1.86 %); half of these happened
to patients with preoperative diagnosis of subcapital fracture
(p = 0.0271). We didn’t obtain statistically significant results for all
the other risk factor analyzed.
Discussion The dislocation incidence in our study is in line with
literature, like the major frequency of dislocation in the patients with
diagnosis of subcapital fracture, which is determined by the greater
ROM in the pre-operative period; this result is supported also by the
highest result in the Harris Hip Score. The offset was restored in all
patients. Abduction and anteversion of the cup were maintained in the
‘‘safe range’’ reported in literature. We obtained a major event of
dislocation in the prosthesis with 28 mm head size, but this result
wasn’t statistically significant.
Conclusions The subcapital fracture resulted as a condition that could
predispose to dislocation of THA. The influence of the femoral head
size, with only 4 mm of difference between the two groups, doesn’t
seem a condition that influences the incidence of dislocation.
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Introduction Achilles tendinopathy is usually associated with neo-
vascularization; color Doppler consents the evaluation of tissue
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